Aspex Management (HK)’s KE Holdings BEKE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q2
Sell
-5,126,453
Closed -$103M 29
2025
Q1
$103M Sell
5,126,453
-1,388,010
-21% -$27.5M 2.65% 15
2024
Q4
$120M Buy
+6,514,463
New +$134M 3.24% 12
2024
Q1
Sell
-4,610,000
Closed -$74.7M 36
2023
Q4
$74.7M Hold
4,610,000
2.19% 16
2023
Q3
$71.5M Sell
4,610,000
-5,773,492
-56% -$91.7M 2.2% 15
2023
Q2
$154M Sell
10,383,492
-2,858,776
-22% -$46.7M 4.48% 9
2023
Q1
$249M Sell
13,242,268
-2,871,083
-18% -$53.2M 6.13% 5
2022
Q4
$225M Buy
16,113,351
+2,662,335
+20% +$37M 6.21% 6
2022
Q3
$236M Sell
13,451,016
-1,048,366
-7% -$17M 6.96% 5
2022
Q2
$260M Buy
14,499,382
+2,500,000
+21% +$35.2M 6.52% 8
2022
Q1
$148M Buy
11,999,382
+2,999,382
+33% +$53.4M 5.87% 8
2021
Q4
$181M Buy
9,000,000
+6,500,000
+260% +$133M 5.54% 7
2021
Q3
$45.6M Hold
2,500,000
1.52% 18
2021
Q2
$119M Hold
2,500,000
3.9% 9
2021
Q1
$142M Sell
2,500,000
-646,514
-21% -$40.6M 5.64% 7
2020
Q4
$194M Buy
3,146,514
+1,033,573
+49% +$68.7M 7.64% 4
2020
Q3
$130M Buy
+2,112,941
New +$106M 8.31% 4

Other funds holding BEKE

Aspex Management (HK)'s BEKE Position: Q2 2025 in Review

Aspex Management (HK) sold out of KE Holdings (BEKE) in Q2 2025, closing a stake of 5,126,453 shares — an estimated $103M sold.

Aspex Management (HK) first reported a position in BEKE in Q3 2020 and held it in 16 quarters. The position peaked at $260M in Q2 2022. 257 funds tracked by Wall St. Rank hold BEKE as of Q2 2025.

  • Aspex Management (HK) reported no remaining KE Holdings position as of Q2 2025 after selling out during the quarter.
  • Aspex Management (HK) sold 5,126,453 KE Holdings shares in Q2 2025, an estimated $103M.
  • Aspex Management (HK) first reported a position in KE Holdings in Q3 2020 and held it in 16 quarters.
  • Aspex Management (HK)'s KE Holdings position peaked at $260M in Q2 2022.
  • 257 funds tracked by Wall St. Rank held KE Holdings as of Q2 2025.

Based on Aspex Management (HK)'s 13F filing for Q2 2025, filed 13 Aug 2025.